Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, for what reason there is a shortage of the drug Trulicity in the NHS.

The Department has been working with Eli Lilly to address issues with access to glucagon-like peptide-1 receptor agonists (GLP-1 RA) for type 2 diabetics. Issues with the supply of Trulicity (dulaglutide) have been driven by an increase in global demand. We have worked closely with Eli Lilly during this time to try to minimise risks to patients in the United Kingdom. As a result, patients stabilised on Trulicity (dulaglutide) should be able to continue to obtain their medicine. The supply of Trulicity will be intermittent throughout 2024 and patients are advised to speak to their prescriber if they have any concerns.

We issued updated guidance to healthcare professionals, in the form of a National Patient Safety Alert, on 3 January 2024, on how to manage patients requiring these medicines.

Our guidance is clear that GLP-1RAs that are solely licensed to treat type 2 diabetes should only be used for that purpose and should not be routinely prescribed for weight loss. The General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and Pharmaceutical Society of Northern Ireland have also issued a joint statement stressing the importance of health and care professionals meeting regulatory standards in relation to these medicines.